[
    "{\"step_by_step_thinking\": \"To answer this question, we need to look at the relevant documents that discuss the efficacy of single-agent mitoxantrone and combination chemotherapy in the treatment of high-risk metastatic breast cancer. Document [1] states that a multicenter randomized trial found no significant difference in survival between single-agent mitoxantrone and combination chemotherapy in high-risk metastatic breast cancer patients. Additionally, Document [14] reports a meta-analysis of nine randomized Phase III trials, which also found no significant difference in overall survival between combination therapy and single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer patients. Based on this information, the answer is B. no.\", \"answer_choice\": \"B\"}"
]